Nova vs Revel Health
Two all-in claims, one of which survives the first month.
Nova
Editorial
$139/mo
Two injection lines quoted as all-in figures that already contain a required care fee: $198 for semaglutide and $210 for tirzepatide, with shipping stated as included. A required fee named inside the price is a different proposition from one a buyer meets at checkout. The oral lines are quoted lower, at $156 and $174, but the oral semaglutide bills its first three months together at $269. Coverage is two states.
Pick it for: Buyers in Texas or Florida comparing an ongoing figure
Revel Health
Editorial
$149/mo
Two injection lines sold on a single-figure promise: Revel states one price covers consultation, medication, supplies and shipping. Semaglutide is quoted from $199 and tirzepatide from $249. Both also advertise a lower first month, which reduces one bill rather than the rate, and both figures are written as 'From', making them floors. Coverage is stated across 45 states.
Pick it for: Buyers who want nationwide coverage and will read past the intro month
Our verdict
Both state their figure covers the service rather than the medication alone. Revel's headline is a first month that ends; Nova's is an ongoing figure that rises with the dose.
What actually separates them
Nova and Revel Health state different things about published price and where you can use it. Everything else they publish, they publish the same way.
Revel Health costs $10 more than Nova — 7% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,668 at Nova against $1,788 at Revel Health — a difference of $120.
| Nova | Revel Health | |
|---|---|---|
| Published price | $139/mo | $149/mo |
| Where you can use it | 2 states | 45 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.